Introduction/Background We investigated the treatment outcomes of immune checkpoint inhibitor (ICI) with modulated electro-hyperthermia (mEHT) in patients with recurrent gynecologic cancers

Methodology We investigated the treatment outcomes of immune checkpoint inhibitor (ICI) with modulated electro-hyperthermia (mEHT) in patients with recurrent gynecologic cancers

Results The median age of the patients was 48 years (range, 44–63). Two, four, and three patients presented with cervical, ovarian, and uterine cancers, respectively. The median line of prior chemotherapy was two (1–5). Mismatch repair deficient or high microsatellite instable tumor was found in two patients, and seven patients’ tumor exhibited more than 1 point at combined positive score (CPS) in programmed cell death ligand-1. Eight patients received pembrolizumab and one received nivolumab with mEHT every two or three times a week in accordance with the timing of the ICI administration. As treatment results, one (11%) and two (22%) patients showed complete response (CR) and partial response (PR), respectively, with a median progression-free survival (PFS) of 6.5 months (range, 0.7–44.1). Two experienced stable disease and four progressions were observed. The median overall survival was 16.7 months (range, 1.3–44.1). There was no treatment discontinuation due to adverse events or treatment related death.

Conclusion This small number study showed that ICI with mEHT for recurrent gynecologic cancers could be feasible without severe adverse events.

Disclosures I have no financial disclosure or conflicts of interests with the presented material in this research.